Turner Investments’s Neurocrine Biosciences NBIX Stock Holding History

Turner Investments’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-44,430	Closed	-$2.25M	–	283
2016 Q3	$2.25M	Buy	+44,430	New	+$2.21M	0.74%	49
2016 Q1	–	Sell	-18,000	Closed	-$1.02M	–	238
2015 Q4	$1.02M	Sell	18,000 -20,000	-53%	-$1.02M	0.21%	136
2015 Q3	$1.51M	Buy	38,000 +16,710	+78%	+$808K	0.31%	102
2015 Q2	$1.02M	Buy	+21,290	New	+$903K	0.19%	168
2014 Q3	–	Sell	-303,950	Closed	-$4.51M	–	555
2014 Q2	$4.51M	Sell	303,950 -240,820	-44%	-$3.4M	0.2%	150
2014 Q1	$8.77M	Sell	544,770 -187,802	-26%	-$3.21M	0.23%	158
2013 Q4	$6.84M	Sell	732,572 -538,742	-42%	-$5.26M	0.12%	222
2013 Q3	$14.4M	Sell	1,271,314 -285,372	-18%	-$3.92M	0.24%	144
2013 Q2	$20.8M	Buy	+1,556,686	New	+$19.1M	0.28%	138

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Turner Investments's NBIX Position: Q4 2016 in Review

Turner Investments sold out of Neurocrine Biosciences (NBIX) in Q4 2016, closing a stake of 44,430 shares — an estimated $2.25M sold.

Turner Investments first reported a position in NBIX in Q2 2013 and held it in 9 quarters. The position peaked at $20.8M in Q2 2013. 225 funds tracked by Wall St. Rank hold NBIX as of Q4 2016.

Turner Investments reported no remaining Neurocrine Biosciences position as of Q4 2016 after selling out during the quarter.
Turner Investments sold 44,430 Neurocrine Biosciences shares in Q4 2016, an estimated $2.25M.
Turner Investments first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 9 quarters.
Turner Investments's Neurocrine Biosciences position peaked at $20.8M in Q2 2013.
225 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2016.

Based on Turner Investments's 13F filing for Q4 2016, filed 8 Feb 2017.